The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries
Open accessAbstract
IMPORTANCE: The burden of cancer falls disproportionally on low-middle-income countries (LMICs). It is not well known how novel therapies are tested in current clinical trials and the extent to which they match global disease burden. OBJECTIVES: To describe the design, results, and publication of oncology randomized clinical trials (RCTs) and examine the extent to which trials match global disease burden and how trial methods and results differ across economic settings. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective cohort study, a literature search identified all phase 3 RCTs evaluating anticancer therapies published from 2014 to 2017. Randomized clinical trials were classified based on World Bank economic classification. Descriptive statistics were used to compare RCT design and results from high-income countries (HICs) and low/middle-income countries (LMICs). Statistical analysis was conducted in January 2020. MAIN OUTCOMES AND MEASURES: Differences in the design, results, and output of RCTs between HICs and LMICs. RESULTS: The study cohort included 694 RCTs: 636 (92%) led by HICs and 58 (8%) led by LMICs. A total of 601 RCTs (87%) tested systemic therapy and 88 RCTs (13%) tested radiotherapy or surgery. The proportion of RCTs relative to global deaths was higher for breast cancer (121 RCTs [17%] and 7% of deaths) but lower for gastroesophageal cancer (38 RCTs [6%] and 14% of deaths), liver cancer (14 RCTs [2%] and 8% of deaths), pancreas cancer (14 RCTs [2%] and 5% of deaths), and cervical cancer (9 RCTs [1%] and 3% of deaths). Randomized clinical trials in HICs were more likely than those in LMICs to be funded by industry (464 [73%] vs 24 [41%]; P < .001). Studies in LMICs were smaller than those in HICs (median, 219 [interquartile range, 137-363] vs 474 [interquartile range, 262-743] participants; P < .001) and more likely to meet their primary end points (39 of 58 [67%] vs 286 of 636 [45%]; P = .001). The observed median effect size among superiority trials was larger in LMICs compared with HICs (hazard ratio, 0.62 [interquartile range, 0.54-0.76] vs 0.84 [interquartile range, 0.67-0.97]; P < .001). Studies from LMICs were published in journals with lower median impact factors than studies from HICs (7 [interquartile range, 4-21] vs 21 [interquartile range, 7-34]; P < .001). Publication bias persisted when adjusted for whether a trial was positive or negative (median impact factor: LMIC negative trial, 5 [interquartile range, 4-6] vs HIC negative trial, 18 [interquartile range, 6-26]; LMIC positive trial, 9 [interquartile range, 5-25] vs HIC positive trial, 25 [interquartile range, 10-48]; P < .001). CONCLUSIONS AND RELEVANCE: This study suggests that oncology RCTs are conducted predominantly by HICs and do not match the global burden of cancer. Randomized clinical trials from LMICs are more likely to identify effective therapies and have a larger effect size than RCTs from HICs. This study suggests that there is a funding and publication bias against RCTs led by LMICs. Policy makers, research funders, and journals need to address this issue with a range of measures including building capacity and capability in RCTs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ethical and Scientific Implications of the Globalization of Clinical Research
Glickman, S. W., McHutchison, J. G., Peterson, E. D., Cairns, C. B., Harrington, R. A., Califf, R. M., & Schulman, K. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmsb0803929 · Cited by 710
Barriers for conducting clinical trials in developing countries—A systematic review
Alemayehu, C., Mitchell, G., & Nikles, J. (2018) · International Journal for Equity in Health · doi:10.1186/s12939-018-0748-6 · Cited by 406
Cancer survival: global surveillance will stimulate health policy and improve equity
Coleman, M. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62225-4 · Cited by 370
Harris, M., Marti, J., Watt, H., Bhatti, Y., Macinko, J., & Darzi, A. W. (2017) · Health Affairs · doi:10.1377/hlthaff.2017.0773 · Cited by 119
Cited by
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Priorities for cancer research in low- and middle-income countries: a global perspective
Pramesh, C. S., Badwe, R. A., Bhoo-Pathy, N., Booth, C. M., Chinnaswamy, G., Dare, A. J., de Andrade, V. P., Hunter, D. J., Gopal, S., Gospodarowicz, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01738-x · Cited by 434
Self-citationBarriers and opportunities for cancer clinical trials in low- and middle-income countries
Eldridge, L., Goodman, N. R., Chtourou, A., Galassi, A., Monge, C., Cira, M. K., Pearlman, P. C., Loehrer, P. J., Gopal, S., & Ginsburg, O. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.7733 · Cited by 28
Sahdra, B. K., King, G., Payne, J. S., Ruiz, F. J., Ali Kolahdouzan, S., Ciarrochi, J., & Hayes, S. C. (2024) · Behavior Therapy · doi:10.1016/j.beth.2024.06.003 · Cited by 25
Yang, K., Li, J., Cheng, Y., & Bai, C. (2023) · Endocrine Connections · doi:10.1530/ec-22-0441 · Cited by 4
Metadata
- Authors
- Wells, J. C., Sharma, S., Del Paggio, J. C., Hopman, W. M., Gyawali, B., Mukherji, D., Hammad, N., Pramesh, C. S., Aggarwal, A., Sullivan, R., & Booth, C. M.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2021-03-01
- Volume
- 7
- Issue
- 3
- Pages
- 379
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W3121373553
- Cited by
- 175
- References
- 4
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.